AlloVir announces positive preliminary Phase 2 data for posoleucel in virus prevention in high-risk allo-HCT patients

Kalaris Therapeutics, Inc.

No end-organ viral disease observed in 23 high-risk allo-HCT patients receiving posoleucel.
Only 3 of 138 possible clinically significant infections occurred; 11 of 13 patients through Week 14 free of infection.
FDA agreed in principle to advance to Phase 3 registrational trial expected to start in 1H 2022.
Posoleucel targeting six viruses: AdV, BKV, CMV, EBV, HHV-6, and JCV.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.